-+ 0.00%
-+ 0.00%
-+ 0.00%

Heplatinum Pharmaceutical-B (02142) signed a global strategic cooperation and licensing agreement with Bristol-Myers Squibb

Zhitongcaijing·12/17/2025 00:25:03
Listen to the news

Zhitong Finance App News and Platinum Pharmaceutical-B (02142) announced that on December 17, 2025, the company and Bristol-Myers Squibb have signed a multi-year global strategic cooperation and licensing agreement to discover and develop a new generation of multi-specific antibodies.

According to the terms of the agreement, Heplatinum Pharmaceuticals will cooperate with Bristol-Myers Squibb to advance and accelerate the discovery of multi-specific antibodies. In return, Heplatin Pharmaceuticals will receive a total payment of 90 million US dollars. If Bristol-Myers Squibb chooses to advance all potential projects, the company can also receive development and commercial milestone payments of up to US$1,035 million and tiered royalties.